Status:
WITHDRAWN
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
Halozyme Therapeutics
Conditions:
Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors. Subjects will re...
Eligibility Criteria
Inclusion
- Signed Informed Consent Form
- Capable of giving informed consent.
- Ability and willingness to comply with the protocol including all scheduled MRI studies and paired tumor biopsies
- Aged ≥ 18 years.
- borderline or unresectable pancreatic adenocarcinoma without distant metastatic disease.
- ECOG PS of 0 or 1
- Must have adequate organ and hematopoietic function
- Female and Males must use an approved contraceptive method
Exclusion
- Received prior therapy for pancreatic adenocarcinoma
- History of deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Contraindication to therapeutic anticoagulation or heparin
- Intolerance to dexamethasone
- Contraindication to MRI or unwillingness to undergo all scheduled MRI exams
- Known or suspected brain metastasis
- Significant cardiovascular disease such as current New York Heart Associate Class III/IV heart failure, myocardial infarction or stroke within 6 months prior to enrollment
- A second primary malignancy that, in the judgment of the investigator, may affect the interpretation of results
- Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint
- Active bacterial or fungal infection requiring IV therapy at the start of protocol treatment
- Subjects may not receive concomitant anticancer agents or radiation.
- Female subjects who are pregnant or nursing
- Pre-existing peripheral neuropathy \> CTCAE Grade 2.
- Known allergy to hyaluronidase
- Current use of megestrol acetate (use within 10 days of Day 1)
- Inability to comply with study and follow-up procedures as judged by the Investigator
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 11 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04134468
Start Date
January 1 2020
End Date
November 11 2022
Last Update
January 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104